Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Corticosteroids are of proven value for the treatment of active ulcerative colitis and Crohn's disease, but are of little value for the maintenance of remission. The development of new steroid compounds with low systemic bioavailability should allow higher doses to be given for longer periods without risking serious adverse reactions.

Type

Journal article

Journal

Gastroenterology clinics of North America

Publication Date

03/1989

Volume

18

Pages

21 - 34

Addresses

Gastroenterology Unit, Radcliffe Infirmary, Oxford.

Keywords

Humans, Colitis, Ulcerative, Crohn Disease, Adrenal Cortex Hormones, Enema, Administration, Topical, Drug Administration Schedule